Hepatocellular Carcinoma Drugs Market Report 2026

Hepatocellular Carcinoma Drugs Market Overview

• Hepatocellular Carcinoma Drugs market size has reached to $1.25 billion in 2025 • Expected to grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular Carcinoma Drug Market • Market Trend: Advanced Immunotherapy Combination Expands Treatment Options For Aggressive Liver Cancer • North America was the largest region in 2025.

What Is Covered Under Hepatocellular Carcinoma Drugs Market?

Hepatocellular carcinoma drug refers to a drug for primary liver cancer originating from hepatocytes, the main type of liver cells. Hepatocellular carcinoma develops in chronic liver diseases, such as chronic hepatitis B or C infection, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), or liver cirrhosis. The main types of hepatocellular carcinoma drugs are brachytherapy and chemotherapy. Brachytherapy is a type of radiation therapy used in the treatment of cancer. It involves the precise placement of radioactive sources directly into or near the tumor site. The radioactive sources used in brachytherapy for HCC include iodine-125 and iridium-192. The various drug classes of hepatocellular carcinoma drugs are PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors that are used in hospitals, clinics, cancer rehabilitation centers, and ambulatory surgical centers.

What Is The Hepatocellular Carcinoma Drugs Market Growth Forecast?

The hepatocellular carcinoma drugs market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to advancements in targeted therapy, growth of immunotherapy drugs, expansion of early screening programs, increasing healthcare infrastructure in emerging markets, rising adoption of personalized medicine. Major trends in the forecast period include targeted therapy development, immunotherapy advancements, personalized medicine adoption, early diagnosis & screening programs, combination therapy research.

Global Hepatocellular Carcinoma Drugs Market Segmentation

1) By Type: Brachytherapy, Chemotherapy 2) By Drug Class: PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors 3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers Subsegments: 1) By Brachytherapy: Radioactive Seed Implants, Balloon-Activated Brachytherapy, Selective Internal Radiation Therapy 2) By Chemotherapy: Systemic Chemotherapy, Targeted Therapy Agents, Combination Chemotherapy Regimens, Adjuvant Chemotherapy

What Is The Driver Of The Hepatocellular Carcinoma Drugs Market?

The rise in the occurrence of hepatocellular carcinoma is expected to propel the growth of the hepatocellular carcinoma drug market over the coming years. Hepatocellular carcinoma (HCC) is a primary malignant disease of the liver and the most common form of liver cancer. Hepatocellular carcinoma starts with the main type of liver cells called hepatocyte cells. Most cases of HCC result from infection with hepatitis B or C, or cirrhosis. As the occurrence of hepatocellular carcinoma continuing to rise, it leads to an increased demand for effective hepatocellular carcinoma drugs to treat the disease. For instance, in 2023, according to the report published by the American Cancer Society, Inc., a US-based nationwide voluntary health organization dedicated to eliminating cancer, estimated new cases of liver cancer in females diagnosed in the United States increased from 12,660 in 2022 to 13,230 in 2023. Therefore, the rise in the occurrence of hepatocellular carcinoma is driving the growth of the hepatocellular carcinoma drug industry.

Key Players In The Global Hepatocellular Carcinoma Drugs Market

Major companies operating in the hepatocellular carcinoma drugs market are AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.

Global Hepatocellular Carcinoma Drugs Market Trends and Insights

Major companies operating in the hepatocellular carcinoma drugs market are focusing on developing innovative products such as immune checkpoint inhibitor combinations to improve treatment outcomes for patients with advanced disease. An immune checkpoint inhibitor combination is a therapeutic regimen that pairs two complementary immunotherapies to enhance the body’s antitumor response by targeting distinct immune regulatory pathways. For instance, in April 2025, the U.S. Food and Drug Administration, a US–based regulatory authority, approved the nivolumab–ipilimumab combination regimen. This dual-agent therapy was authorized for first-line treatment of adults with unresectable or metastatic hepatocellular carcinoma after demonstrating superior overall survival and response rates compared with existing therapeutic options. It introduces a clinically validated immunotherapy alternative that broadens the systemic treatment landscape for advanced liver cancer.

What Are Latest Mergers And Acquisitions In The Hepatocellular Carcinoma Drugs Market?

In August 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired Chinook Therapeutics Inc. for a deal of $3.2 billion. Through this acquisition, Novartis aims to harness the collective resources and expertise to advance the development of promising treatments for individuals with rare, severe chronic kidney diseases. The integration of the Chinook team is anticipated to support Novartis in expanding its renal portfolio and contribute to its ongoing commitment to redefining medicine. Chinook Therapeutics Inc. is a US-based company that develops treatments for rare, severe chronic kidney disorders, including hepatocellular carcinoma (HCC).

Regional Insights

North America was the largest region in the hepatocellular carcinoma drug market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hepatocellular Carcinoma Drugs Market?

The hepatocellular carcinoma drug market consists of revenues earned by entities by providing surgery, radiofrequency ablation, and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatocellular carcinoma drug market also includes sales of cabozantinib, ramucirumab and pembrolizumab drugs used for the treatment of hepatocellular carcinoma drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hepatocellular Carcinoma Drugs Market Report 2026?

The hepatocellular carcinoma drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hepatocellular carcinoma drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.